誉衡药业
(002437)
| 流通市值：73.43亿 | | | 总市值：78.49亿 |
| 流通股本：20.86亿 | | | 总股本：22.30亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 539,105,711.33 | 2,135,451,494.88 | 1,664,997,338.49 | 1,099,501,266.79 |
| 营业收入 | 539,105,711.33 | 2,135,451,494.88 | 1,664,997,338.49 | 1,099,501,266.79 |
| 二、营业总成本 | 463,882,978.06 | 1,906,201,168.54 | 1,463,760,914.56 | 977,868,310.54 |
| 营业成本 | 293,392,928.78 | 1,167,082,041.34 | 892,117,691.73 | 579,512,077.52 |
| 税金及附加 | 8,234,491.95 | 32,945,250.04 | 25,187,399.78 | 16,446,942.36 |
| 销售费用 | 127,223,530.82 | 496,289,795.89 | 411,395,500.83 | 294,238,047.8 |
| 管理费用 | 22,688,402.02 | 131,797,389.7 | 85,874,163 | 56,753,730.91 |
| 研发费用 | 11,570,107.05 | 78,427,205.91 | 49,714,579.12 | 30,316,235.75 |
| 财务费用 | 773,517.44 | -340,514.34 | -528,419.9 | 601,276.2 |
| 其中:利息费用 | 916,345.81 | 2,480,335.32 | 1,795,775.39 | 2,340,656.38 |
| 其中:利息收入 | 1,387,168.03 | 5,095,443.46 | 3,723,490.24 | 2,546,567.2 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 17,633,869.7 | 5,977,821.1 | 37,690,053.1 | 8,559,844.12 |
| 加:投资收益 | 435,988.1 | 136,525,191.03 | -565,419.78 | 175,170.34 |
| 资产处置收益 | 11,157,869.1 | 3,542,703.45 | 3,672,501.28 | 3,660,243.29 |
| 资产减值损失(新) | -405,377.25 | -10,279,426.44 | -930,377.77 | -906,206.2 |
| 信用减值损失(新) | -34,974.87 | 26,330.79 | 16,215.64 | -4,538.7 |
| 其他收益 | 3,258,797.56 | 39,868,070.65 | 24,134,568.42 | 18,755,923.47 |
| 四、营业利润 | 107,268,905.61 | 404,911,016.92 | 265,253,964.82 | 151,873,392.57 |
| 加:营业外收入 | 7,980.66 | 6,330,581.64 | 4,996,334.88 | 458,669.14 |
| 减:营业外支出 | 146,925.43 | 1,624,660.95 | 916,973.7 | 243,050.22 |
| 五、利润总额 | 107,129,960.84 | 409,616,937.61 | 269,333,326 | 152,089,011.49 |
| 减:所得税费用 | 10,462,749.51 | 27,259,809.86 | 21,409,752.07 | 14,664,998.51 |
| 六、净利润 | 96,667,211.33 | 382,357,127.75 | 247,923,573.93 | 137,424,012.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 96,667,211.33 | 382,357,127.75 | 247,923,573.93 | 137,424,012.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 94,926,073.47 | 376,905,170.2 | 243,763,036.93 | 134,422,001.01 |
| 少数股东损益 | 1,741,137.86 | 5,451,957.55 | 4,160,537 | 3,002,011.97 |
| 扣除非经常损益后的净利润 | 62,942,231.17 | 199,145,728.83 | 178,162,705.84 | 106,654,653.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.17 | 0.11 | 0.06 |
| (二)稀释每股收益 | 0.04 | 0.17 | 0.11 | 0.06 |
| 八、其他综合收益 | -1,530,963.76 | -1,098,908.06 | -639,692.29 | -159,250.63 |
| 归属于母公司股东的其他综合收益 | -1,530,963.76 | -1,098,908.06 | -639,692.29 | -159,250.63 |
| 九、综合收益总额 | 95,136,247.57 | 381,258,219.69 | 247,283,881.64 | 137,264,762.35 |
| 归属于母公司股东的综合收益总额 | 93,395,109.71 | 375,806,262.14 | 243,123,344.64 | 134,262,750.38 |
| 归属于少数股东的综合收益总额 | 1,741,137.86 | 5,451,957.55 | 4,160,537 | 3,002,011.97 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-29 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |